In today’s Pharmaceutical Executive Daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, ...
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...
Boehringer Ingelheim announced a license and collaboration agreement with Simcere Pharmaceuticals to develop Simcere’s ...
Pharmaceutical and life sciences organizations operate under extraordinary regulatory pressure. FDA, EMA, MHRA, and GxP ...
Pharmaceutical Executive: What trends did you see at this year's JP Morgan Healthcare Conference? Clay Siegall: I’ve been ...
In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million ...
Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...
According to a report from CNN, more states and pediatricians are now choosing the AAP’s guidance over a revised federal ...
Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...
Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while ...
The United States’ official exit from the World Health Organization (WHO) is set to be finalized today, Thursday January 22, ...
In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results